The significant morbidity and mortality of people with end-stage renal, liver, heart, and lung diseases in need of transplantation provides rationale for use of organs from donors who are hepatitis B positive. The recipient's hepatitis B status plays a key role in defining the prophylactic strategy. The availability of safe and effective therapies (hepatitis B antivirals and hepatitis B immune globulin) has contributed to the safety of using hepatitis B-positive donors. The outcomes in both liver and nonliver solid organ transplant recipients given hepatitis B-positive organs have been excellent if appropriate prophylactic therapies provided.
Keywords: Antibody to hepatitis B core; Donor-transmitted hepatitis; Hepatitis B immunoglobulin; Hepatitis B surface antigen; Reactivation.
Copyright © 2021 Elsevier Inc. All rights reserved.